Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis

Calcified Tissue International

Volumn 95, Issue 4, 2014, Pages 295-307

  Frediani, B ^a   Baraldi, E ^b   Cremonesi, G ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Bone fracture; Cancer; Clodronate; Osteoporosis; Systematic review

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID;

DRUG EFFECTS; FEMALE; FRACTURE HEALING; FRACTURES, BONE; HUMAN; MALE; META ANALYSIS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; FEMALE; FRACTURE HEALING; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PROBABILITY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84931028561     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-014-9903-2     Document Type: Review

References (51)

1. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320–323
2. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739
3. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556–561
4. Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD (2011) Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 22(9):2439–2448
5. Rostom S, Allali F, Bennani L, Abouqal R, Hajjaj-Hassouni N (2012) The prevalence of vertebral fractures and health-related quality of life in postmenopausal women. Rheumatol Int 32(4):971–980
6. Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W, Italian Multicentre Osteoporotic Fracture Study Group (2007) The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 34(7):1551–1560
7. Lustberg MB, Reinbolt RE, Shapiro CL (2012) Bone health in adult cancer survivorship. J Clin Oncol 30(30):3665–3674
8. Roodman GD (2004) Mechanisms of bonemetastasis. N Engl J Med 350(16):1655–1664
9. Winter MC, Coleman RE (2013) Bisphosphonates in the adjuvant treatment of breast cancer. Clin Oncol (R Coll Radiol) 25(2):135–145
10. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593
11. Kawatani M, Osada H (2009) Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases. Cancer Sci 100(11):1999–2005
12. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev, CD003474
13. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16(2):593–602
14. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387
15. Ghinoi V, Brandi ML (2002) Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother 3(11):1643–1656
16. Frediani B, Cavalieri L, Cremonesi G (2009) Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig 29(6):359–379
17. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44(9):2201–2210
18. Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, Boldrini S, Troiani S, Massoni C (1996) Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 18(2):179–184
19. McCloskey E, Selby P, de Takats D, Bernard J, Davies M, Robinson J, Francis R, Adams J, Pande K, Beneton M, Jalava T, Löyttyniemi E, Kanis JA (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28(3):310–315
20. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19(5):728–736
21. Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH (1988) Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 42(2):111–116
22. Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH (1987) Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 8(Suppl 1):S53–S56
23. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113(4):1035–1043
24. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100(2):317–325
25. Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ (1982) Long-term effects of dichloromethylenediphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 4(3):163–168
26. Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E (1990) Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 8(1):23–30
27. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev, 5:CD003188. doi:10.1002/14651858.CD003188.pub3
28. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19
29. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16(27):2950–2960
30. Berenson JR (2011) Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support Palliat Care 5(3):233–240
31. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(1):420–432
32. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghé F, Pannuti F (1991) Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48(2):97–101
33. Tanakol R, Yarman S, Bayraktaroglu T, Boztepe H, Alagöl F (2007) Clodronic acid in the treatment of postmenopausal osteoporosis. Clin Drug Investig 27(6):419–433
34. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340(8827):1049–1052
35. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88(7):701–707
36. Beard MK (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Curr Med Res Opin 28(1):141–147
37. Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22(3):741–753
38. Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R (2003) Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 33(4):575–581
39. Tauchmanova L, Guerra E, Pivonello R, De Martino MC, De Leo M, Caggiano F, Lombardi G, Colao A (2009) Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome. J Endocrinol Invest 32(5):390–394
40. Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and non vertebral-non hip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(4):275–284
41. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24(1):237–245
42. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880
43. Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71(1):65–78
44. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1):59–65
45. Clemens MR, Fessele K, Heim ME (1993) Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 66(3):141–146
46. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19(6):663–667
47. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74
48. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19(1):10–17
49. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK, Mrc Pr05 Collaborators (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95(17):1300–1311
50. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8(2):R13
51. McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22(1):135–141